Navigation Links
Boston Scientific Announces Schedule for European Society of Cardiology Congress
Date:8/27/2009

ect," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
2. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
3. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
4. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
5. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
8. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
9. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
10. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
11. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Since last month,s FBI shutdown of online ... the leading online black market for illegal drugs - ... offering of drugs and other illegal items.  New numbers ... succeed in lowering the numbers of drugs and illegal ... in August. But some new sites that have emerged ...
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS Asserts its Position in Difficult Environment 2
... 21 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... of its,collaboration with the National Institute of ... institute supporting biodefense,research, under which the NIAID ... late-stage antibiotic, as a treatment for,anthrax and ...
... By ... Year- End 2007, ... focused on discovering and,developing novel RNA interference-based therapeutics, announced today that,it ... at,Buffalo, Center for Hearing & Deafness, which is the Company,s primary ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:12/19/2014)... Oshkosh, Wisconsin (PRWEB) December 19, 2014 ... country music performer is again returning to the stage ... joining her husband for concert performances, and the successful ... show was originally announced. , Visit Ticketability.com ... for the newly-announced Detroit shows at fair prices. , ...
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... Randy Dotinga HealthDay ... -- Common painkillers, including ibuprofen, might slightly reduce your ... say. Use of ibuprofen (Advil, Motrin) and naproxen ... skin cancer by 15 percent, the researchers concluded after ... usually caused by sun exposure. These ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3
... 14 (HealthDay News) -- Military veterans who attempt suicide are ... have an overall heightened risk of death from all causes, ... in BioMed Central Public Health , looked at the ... Veterans Affairs medical center for a suicide attempt between 1993 ...
... THURSDAY, July 14 (HealthDay News) -- Before the advent of ... information -- such as phone numbers and birthdays -- than you ... the brain just doesn,t remember information as well if the person ... people may remember, however, is where they need to ...
... part of the Target Safely initiative, the American Society for ... of a series of such papers, on the safe use ... oncology clinic. The executive summary of this white paper is ... (PRO), ASTRO,s clinical practice journal. The full text of the ...
... 14 July 2011 Bristol-Myers Squibb today announced that ... treatment of adult patients with previously-treated advanced melanoma. ... the treatment of patients with advanced melanoma in a ... England Journal of Medicine in June 2010.(1) Based ...
... Whether patients with type 2 diabetes mellitus benefit from ... levels through treatment ("intensive blood glucose control") remains an ... a benefit but also of potential harm. This is ... Institute for Quality and Efficiency in Health Care (IQWiG). ...
... , WEDNESDAY, July 13 (HealthDay News) -- A new study ... patients thinking that real and fake drugs were doing the ... had a much greater physical effect on their lungs. ... were breathing much better even if they hadn,t taken a ...
Cached Medicine News:Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:ASTRO publishes white paper on IMRT safety 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 3Health News:Benefit of blood glucose lowering to near-normal levels remains unclear 2Health News:Benefit of blood glucose lowering to near-normal levels remains unclear 3Health News:Delving Into the Mystery of Placebos 2Health News:Delving Into the Mystery of Placebos 3
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
... The ANGIO CT MIYABI ... a Siemens SOMATOM CT scanner ... an AXIOM Multistar angiography unit. ... M angio table, which can ...
Medicine Products: